PLC () has filed a new patent application for its CDX antibody.
It covers its use in conditioning patients for bone marrow transplant and its deployment in a number of hard-to-treat blood borne diseases, including acute myeloid leukaemia (AML).
On the latter, the application covers the composition sequences of newly-discovered monoclonal antibodies against a target protein expressed on the surface of hematopoietic stem cells of certain types of leukaemia.
“Filing this patent is an important development and further solidifies Hemogenyx’s leadership position in the development of new methods of bone marrow transplantation and treatments for blood cancers such as AML, acute lymphoblastic leukemia and possibly others,” said Hemogenyx chief executive, Dr Vladislav Sandler.
“The antibody we are developing, CDX, should, if successful, provide a new, effective and safe method of conditioning patients for bone marrow transplants, and has the potential to be a superior pharmaceutical for the treatment of blood cancers, for which survival rates are currently very poor.”
- [LLODO] Pandemic-weary chefs, cooks enjoy serving from home
- [LLODO] 6-year-old gets hero’s welcome back to school after completing cancer treatment
- [LLODO] Missing California hiker found safe after public helps rescuers trace location of photo he sent friend
- [LLODO] California promotes ‘dismantling racism in mathematics’ guidance in draft for statewide framework
- [LLODO] California gold rush town votes to remove controversial nickname and logo
- [LLODO] Three Idaho children reported missing, may be together, sheriff’s office says
- [LLODO] Capitol riot: Police officer won’t face charges in fatal shooting of Ashli Babbitt, prosecutors say
- [LLODO] Former California Democratic mayor charged with multiple sex crimes against child
- [LLODO] California school district to vote on whether high-speed broadband is a human right